{"id":2104,"name":"Astellas Venture Management","slug":"astellas-venture-management","website":"https://www.astellasventure.com","hqGeo":"Menlo Park, CA","stageFocus":["Seed","Pre-Seed"],"sectorTags":["Healthcare","AI / ML"],"excludedSectors":[],"checkSizeMin":1500000,"checkSizeMax":10000000,"thesisSummary":"Astellas Venture Management invests in early-stage therapeutic innovation, focusing on biopharma and AI-based drug design.","thesisNarrative":null,"logoUrl":null,"aumUsd":67500000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"Atomwise","companyUrl":null,"stage":null,"sector":"AI Drug Discovery","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Vector BioPharma","companyUrl":null,"stage":null,"sector":"Biotech","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"DeepSeq.AI","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Serna Bio","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Solu Therapeutics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Develops therapeutics targeting soluble targets in immunology and inflammation.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"PhoreMost","companyUrl":null,"stage":"Series B - II","sector":"Oncology (immuno-oncology)","investmentYear":null,"description":"UK-based developer of small molecule neoantigen immuno-oncology therapies.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Somite Therapeutics","companyUrl":null,"stage":"Pre-Seed - II","sector":"Regenerative medicine (muscle)","investmentYear":null,"description":"Builds cellular therapies for muscle diseases using stem cell tech.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Turn Biotechnologies","companyUrl":null,"stage":null,"sector":"Health/Medical (regenerative)","investmentYear":null,"description":"Develops mRNA-based therapies for cellular rejuvenation in age-related diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"CoMentis","companyUrl":null,"stage":null,"sector":"Biotechnology (neuro)","investmentYear":null,"description":"Focuses on neurodegenerative disease therapies targeting protein misfolding.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Avilar Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology (degradation)","investmentYear":null,"description":"Engineers protein degradation platforms for autoimmune and inflammatory diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Casma Therapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology (autophagy)","investmentYear":null,"description":"Advances autophagy-based therapies for neurodegeneration and metabolic diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Catamaran Bio","companyUrl":null,"stage":null,"sector":"Oncology (immunotherapy)","investmentYear":null,"description":"Develops allogeneic CAR-NK therapies for cancer.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Cleave Biosciences","companyUrl":null,"stage":null,"sector":"Biotechnology (degradation)","investmentYear":null,"description":"Targets protein degradation for cancer and immune diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"CODA Biotherapeutics","companyUrl":null,"stage":null,"sector":"Biotechnology (neuro, antibodies)","investmentYear":null,"description":"Engineers multispecific antibodies for neurological disorders.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Heartseed","companyUrl":null,"stage":"exited","sector":"Regenerative (cardiology)","investmentYear":null,"description":"Cardiac regenerative therapies.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Potenza Therapeutics","companyUrl":null,"stage":"Acq - Fin","sector":"Oncology","investmentYear":null,"description":"Immunotherapy platforms.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Syntax Bio","companyUrl":null,"stage":"Series A","sector":"biotech","investmentYear":null,"description":"Cell therapy company developing regenerative medicine via its proprietary Cellgorithm platform","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Restore Vision","companyUrl":null,"stage":"convertible note / unspecified round","sector":"biotech / ophthalmology","investmentYear":null,"description":"Developer of vision-restoration therapeutics","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Sidewinder Therapeutics","companyUrl":null,"stage":"Series B","sector":"biotech / oncology","investmentYear":null,"description":"Developer of precision bispecific antibody-drug conjugates for cancer","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":1,"partners":[{"id":21335,"name":"William Watt, Ph.D.","title":"President","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/william-watt-phd-1b1a1a8","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsThisYear":0},"activityItems":[],"contentUpdatedAt":"2026-11-20T05:08:38.500Z","investorType":"vc","preferredApproach":"cold outreach ok","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":7722,"name":"Sheesha Finance","slug":"sheesha-finance","logoUrl":null,"website":"https://sheeshafinance.gitbook.io/","stageFocus":[],"sectorTags":["AI / ML","Developer Tools","Fintech"],"hqGeo":null},{"id":13762,"name":"NeuroNet Ventures","slug":"neuronet-ventures","logoUrl":null,"website":"https://neuronetgpo.com/","stageFocus":["Seed"],"sectorTags":["AI / ML"],"hqGeo":"Chicago, IL"},{"id":11767,"name":"LiftScale Partners","slug":"liftscale-partners","logoUrl":null,"website":"https://weareliftscale.com/","stageFocus":["Pre-Seed"],"sectorTags":["AI / ML","SaaS"],"hqGeo":"San Francisco, CA"},{"id":11323,"name":"Mountain Pine Capital","slug":"mountain-pine-capital","logoUrl":null,"website":"https://mountainpineholdings.com/","stageFocus":["Seed"],"sectorTags":["Consumer","Healthcare","Real Estate"],"hqGeo":"Salt Lake City, UT"},{"id":1574,"name":"Plaid Ventures","slug":"plaid-ventures","logoUrl":null,"website":"https://plaid.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Fintech","Developer Tools","AI / ML"],"hqGeo":"San Francisco, CA"},{"id":1621,"name":"Canary","slug":"canary","logoUrl":null,"website":"https://www.canary.capital/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Fintech","AI / ML","SaaS","Healthcare","Enterprise"],"hqGeo":"São Paulo, Brazil"}],"featuredIn":[{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"ai","displayName":"AI & ML Investors","pageType":"industry"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"what-vcs-actually-look-for-pitch-deck","title":"What VCs Actually Look for in a Pitch Deck"},{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"},{"slug":"investormatch-mcp-server-claude-chatgpt","title":"Your Investor List Now Lives Inside Claude and ChatGPT"}],"overviewNarrative":"Astellas Venture Management is a venture capital firm headquartered in Menlo Park, California. The firm invests in early-stage therapeutic innovation with a focus on biopharma and AI-based drug design.\n\nAstellas Venture Management participates in seed and early stage financings. It invests in the sectors of PharmaTech, Healthcare, AI Drug Discovery, and AI/ML. Typical check sizes range from $1.5M to $10.0M. The firm has $68M in assets under management. Cold outreach is an accepted approach.","portfolioNarrative":"Astellas Venture Management has recorded investments in 19 companies. Its portfolio includes Atomwise in AI Drug Discovery, Avilar Therapeutics and Cleave Biosciences in biotechnology focused on degradation, Casma Therapeutics in biotechnology focused on autophagy, and Catamaran Bio in oncology immunotherapy. Additional investments include CODA Biotherapeutics in biotechnology addressing neuro and antibodies, CoMentis in biotechnology focused on neuro, DeepSeq.AI, Heartseed in regenerative cardiology, PhoreMost in oncology and immuno-oncology, and Potenza Therapeutics in oncology.\n\nThe firm has also invested in Restore Vision in biotech and ophthalmology, Serna Bio, Sidewinder Therapeutics in biotech and oncology, and Solu Therapeutics. Portfolio companies have reached stages including Series B, convertible note, and outcomes such as exit and acquisition.","seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-05-04T00:16:06.544Z"}